AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Samsung Medical Centre, Seoul, Korea. Additional 0~5 Korea Lung Cancer Consortium (KLCC)
centres in Korea Up to 40 subjects will be enrolled in two-stages (first stage: 19 evaluable
subjects and second stage: 17 evaluable subjects and additional 4 subjects considering the
drop out rate) If the study is conducted as de-escalated dosage (Durvalumab 1120mg) after the
safety run-in, number of the patients will be counted from the second safety-run in phase.